<DOC>
	<DOCNO>NCT02722941</DOCNO>
	<brief_summary>The purpose study learn way prevent delay relapse multiple myeloma ( MM ) . This study determine best dose schedule LBH589 maintenance therapy well safety ( side effect ) tolerability LBH589 maintenance therapy autologous hematopoietic cell transplant ( HCT ) .</brief_summary>
	<brief_title>Panobinostat ( LBH589 ) : Multiple Myeloma - Autologous Hematopoietic Cell Transplantation ( HCT )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Adult patient , age ≥ 18 year old Ability provide write informed consent obtain prior participation study relate procedure perform Histologically confirm diagnosis multiple myeloma Meeting Criteria Symptomatic Multiple Myeloma ( CRAB criterion ) initiation systemic chemotherapy Received highdose melphalan ( ≥ 140 mg/m^2 ) follow autologous HCT base institutional guideline within +45 +180 autologous HCT time panobinostat maintenance initiation Must achieve least partial response ( PR ) prior autologous HCT must progressive disease ( PD ) prior initiation maintenance therapy Must meet follow laboratory criterion ( prior initiation panobinostat maintenance ) : Absolute neutrophil count ( ANC ) ≥ 1 x 10^9/L ; Hemoglobin ≥ 8 g/dl ; Platelets ≥ 50 x 10^9/L ( without transfusion support ) ; Creatinine clearance ≥ 40 ml/min serum creatinine ≤ 2.5 x upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ; Serum bilirubin ≤ 1.5 x ULN ; Albumin &gt; 3.0 g/dl ; Clinically euthyroid . Note : Participants permit receive thyroid hormone supplement treat underlying hypothyroidism . Baseline ( preHCT ) multigated acquisition ( MUGA ) echocardiogram ( ECHO ) must demonstrate leave ventricular ejection fraction ( LVEF ) ≥ limit normal ( LLN ) institutional normal Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Karnofsky performance status ≥ 70 % Prior histone deacetylase ( HDAC ) , deacetylase ( DAC ) , HSP90 inhibitor valproic acid treatment cancer allow Potential participant purely nonsecretory multiple myeloma ( i.e. , absence measurable protein serum electrophoresis immunofixation absence BenceJones protein urine define use electrophoresis immunofixation ) Prior allogeneic HCT Prior solid organ transplant require immunosuppressive therapy Potential participant need valproic acid medical condition study within 5 day prior first panobinostat treatment Impaired cardiac function clinically significant cardiac disease Diarrhea &gt; Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 Other concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) include abnormal laboratory value , could cause unacceptable safety risk compromise compliance protocol Using medication relative risk prolong QT interval induce torsade de pointes treatment discontinue switched different medication prior start study drug Have receive target agent within 2 week within 5 halflives agent active metabolite ( whichever longer ) recover side effect therapy . Have receive either immunotherapy within &lt; 8 week ; chemotherapy within &lt; 4 week ; radiation therapy &gt; 30 % marrowbearing bone within &lt; 2 week prior start study treatment ; yet recover side effect therapy Have undergone major surgery ≤ 4 week prior start study drug recover side effect therapy Women pregnant breast feed woman childbearing potential ( WOCBP ) use effective method birth control . WOCBP must negative serum pregnancy test within 24 hour receive first dose study medication . Male patient whose sexual partner WOCBP use effective birth control A prior malignancy last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) Known positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Any significant history noncompliance medical regimen unwilling unable comply instruction give him/her study staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>autologous hematopoietic cell transplant ( HCT )</keyword>
	<keyword>autologous</keyword>
</DOC>